Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system for which there is currently no cure. Interferon-beta-1-alpha is worldwide one of the most widely used treatments in multiple sclerosis. To our knowledge there is one previous reported case of rhabdomyolysis associated with Interferon-beta treatment. Case presentation We describe a 30 year old man with relapsing remitting multiple sclerosis who developed rhabdomyolysis and increased creatine kinase following Interferon-beta-1-alpha therapy. After the medication was discontinued, the patient rapidly improved. Conclusion Clinicians should be aware of the possibility of rhabdomyolysis occurring during Interferon-beta-1-alpha therapy. In cases where patients complain of severe myalgia, and in particular if weakness is reported, creatine kinase activity should be measured to prevent irreversible rhabdomyolysis during Interferon-beta-1-alpha therapy in patients with multiple sclerosis.
| Original language | English |
|---|---|
| Journal | Multiple Sclerosis and Related Disorders |
| Volume | 8 |
| Pages (from-to) | 93-95 |
| Number of pages | 3 |
| ISSN | 2211-0348 |
| DOIs | |
| Publication status | Published - Jul 2016 |
Keywords
- Adverse effect
- Interferon-beta treatment
- Multiple sclerosis
- Quality of life
- Rhabdomyolysis